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OBJECTIVES The aim of our study was to evaluate arterial embolism (AE) occurrence rates and predictors
in patients suffering from bradycardia and wearing a pacemaker with antitachycardia pacing
therapies.
BACKGROUND Atrial fibrillation (AF) is associated with a high incidence of AE.
METHODS A total of 725 patients (360 men, age 71  11 years) were implanted with a DDDRP
pacemaker (Medtronic AT500, Medtronic Inc., Minneapolis, Minnesota). At baseline 225
(31.0%) patients received antiplatelet therapy and 264 (36.4%) patients received anticoagu-
lation agents.
RESULTS Over a median 22-month follow-up (25th to 75th interquartile range 16 to 30 months), AE
occurred in 14 (1.9%) patients: 7 patients suffered a nonfatal ischemic stroke (0.6% per year),
4 patients had transient ischemic attack (0.34% per year), and 3 patients had embolic
complications. Among baseline patients’ characteristics, multivariate logistic analysis showed
that embolic events are independently associated to ischemic heart disease (7.0 odds ratio
[OR], 95% confidence interval [CI] 2.3 to 21.3, p  0.001), prior embolic event (7.3 OR,
95% CI 1.2 to 43.9, p  0.029), diabetes (5.0 OR, 95% CI 1.2 to 15.7, p  0.032), and
hypertension (4.1 OR, 95% CI 1.1 to 15.6, p  0.036). The risk of embolism, adjusted for
known risk factors, was 3.1 times increased (95% CI 1.1 to 10.5, p  0.044) in patients with
device-detected atrial fibrillation episodes longer than one day during follow-up.
CONCLUSIONS In a cohort of patients with bradycardia and AF, arterial embolism was common in patients
with ischemic cardiopathy, hypertension, diabetes mellitus, and in patients with known stroke
risk factors. Atrial fibrillation occurrences longer than one day were independently associated
with embolic events. (J Am Coll Cardiol 2005;46:1913–20) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.044College of Cardiology Foundation
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Ptrial fibrillation (AF) is very common in patients with
radycardia undergoing cardiac pacemaker implantation
1–4). Nonvalvular AF has been recognized as a cause of
ortality (5) and in particular it has been associated to a
ve-fold increase in the risk of ischemic stroke, probably
ssociated to atrioembolic mechanism (6–9). Atrial fibrilla-
ion is present in 6% to 24% of patients who have an
schemic stroke, and in up to 50% of patients with cardio-
mbolic strokes (10,11). Annual rate of embolic events in
radycardia patients has been measured in the range be-
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ccepted July 4, 2005.ween 6% and 10% (12–14). Yearly incidence of ischemic
troke in pacemaker patients with sinus node disease has
een recently measured between 1% (3) and 1.4% (15).
The Mode Selection Trial (MOST) atrial diagnostics
ncillary study (16) recently showed that atrial high rate
pisodes detected by an implanted pacemaker in sinus node
isease patients are associated with a two-fold increase in
he risk of death or stroke. Thus, early identification of
atients with AF recurrences may have clinical importance.
The aim of this prospective multicenter observational study
as to assess the incidence of arterial embolic events in patients
uffering from bradycardia and symptomatic paroxysmal or
ersistent AF and therefore implanted with pacemakers able to
eliver antitachycardia therapies. We also aimed to find pre-
ictors of arterial embolic events and to evaluate the clinical
ignificance of AF as detected by pacemaker diagnostics.
ETHODS
atients suffering from bradycardia, having at least a class I
r II American College of Cardiology/American Heart
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Arterial Embolism in Bradycardia Patients November 15, 2005:1913–20ssociation indication for dual-chamber pacing (17) and a
istory of symptomatic atrial tachyarrhythmias (at least
hree symptomatic episodes within the last year before
mplant, one episode in the last month before implant, and
lectrocardiogram or 24-h Holter monitoring documenta-
ion of at least one of these episodes) were eligible for study
articipation.
ntithrombotic therapy. The choice of drug treatment to
revent embolism was performed by each attending physi-
ian, who decided according to the patient’s clinical condi-
ion and his own experience and preferences.
evice characteristics and programming. The Medtronic
T500 (Medtronic Inc., Minneapolis, Minnesota) is a
ual-chamber rate-responsive pacemaker, with advanced
lgorithms designed for rhythm discrimination and preven-
ion and treatment of atrial arrhythmias, as previously
escribed (18,19). Programming of conventional pacemaker
arameters were left to physician discretion. Paced and
ensed atrioventricular delays were programmed with the
im of promoting intrinsic atrioventricular conduction as
uch as possible.
etection of atrial arrhythmias. The implanted devices
ontinuously classify the rhythm status of each patient: it
ases the classification on the PR Logic (Medtronic Inc.)
lgorithm (20,21), which has been previously tested on this
evice and showed 100% sensitivity, 97% specificity (18),
nd 100% positive predictive value (95% confidence interval
CI] in the range 96% to 100%) (21) for atrial tachyarrhyth-
ia detection.
ata analysis. Data about arterial embolic events were
btained at follow-up visits and, when necessary, by a
elephone contact. An outcome committee of two physi-
ians evaluated arterial embolic events, defined as the
ccurrence of ischemic stroke, transient ischemic attack
TIA), or peripheral arterial embolism. Ischemic stroke was
efined as a neurological deficit with sudden onset, persist-
ng for more than 24 h.
We considered as risk factors for embolic events: prior
schemic stroke or TIA, age 75 years, ejection fraction
35%, left atrium diameter 50 mm, ischemic heart
isease, hypertension, heart failure, and diabetes. Patients
ere stratified according to the number of such risk factors
t enrollment.
The possible association between AF occurrence and
mbolic events was studied by stratifying patients according
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
CTOPP  Canadian Trial Of Physiologic Pacing
IQR  interquartile range
MOST  Mode Selection Trial
OR  odds ratio
TIA  transient ischemic attacko their device-calculated duration of AF recurrences ob- werved at follow-up. Prespecified AF duration were at least
min of AF (recognized as an appropriate cutoff to select
F episodes and discard premature atrial contraction runs
r spurious events [22]), and 1 day duration (which is the
ew measurement used in device diagnostics that daily
ollects long-term information about AF), during the whole
bservational period. An episode review committee of three
hysicians evaluated atrial electrograms of AF episodes
aved in device diagnostics to verify detection appropriate-
ess.
tatistical analysis. Descriptive statistics were calculated
sing mean and standard deviation for normally distributed
ontinuous variables, or median with 25th to 75th inter-
uartile range (IQR) in case of skewed distributions. Skew-
ess and kurtosis values were calculated, in order to docu-
ent a normal distribution of each studied parameter.
bsolute and relative frequencies were calculated for cate-
orical variables.
Logistic models were fitted to evaluate patients’ clinical
haracteristics associated with embolic events. Odds ratios
OR) and their 95% CIs were computed. Odds ratio
xpresses the increased (OR 1) or decreased (OR 1)
mbolism risk, according to the examined characteristic.
ariables that showed a p  0.2 when compared for
omogeneity between groups of patients with and without
mbolic events were included in the univariate analysis.
fter checking for collinearity, variables that showed a
ignificant (p  0.05) correlation with embolic events at
nivariate analysis were considered in the multivariate
ogistic models.
Cox proportional hazards models were used to examine
he association between occurrence of AF episodes, longer
han 5 min and longer than 1 day, and the occurrence of
mbolic events. Atrial fibrillation recurrences contributed to
he models as time-dependent covariates, with patients
ntering the AF risk class at the time of the first AF episode.
odels were adjusted for other known embolism predictors.
Comparisons of continuous variables were performed by
wo-tailed unpaired Student t test for normally distributed
ariables and by Mann-Whitney test for variables with
kewed distribution. Comparisons of categorical variables
ere performed by means of Fisher exact test for extreme
roportions or chi-square otherwise.
Curves for survival to embolic events were calculated
sing the Kaplan-Meier method and displayed for the entire
atient population and for patients subgroups selected as a
unction of AF recurrence in the follow-up. Kaplan-Meier
urves comparison was performed by log-rank test. All
eported p values are two-tailed. SPSS software (version
1.5 statistical package, SPSS Inc., Chicago, Illinois) was
sed for all the statistical analysis.
ESULTS
etween September 1999 to December 2003, 725 patients
ere enrolled in 83 cardiology departments (Appendix)
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November 15, 2005:1913–20 Arterial Embolism in Bradycardia Patientsfter they received a DDDR pacemaker (AT500, Medtronic
nc.). Pacing indication was sinus node disease in 600
82.8%) patients, atrioventricular block in 34 (4.7%) pa-
ients, drug-induced bradycardia in 32 (4.4%) patients,
ther in 59 (8.1%) patients. A review of patients clinical
haracteristics is shown in Table 1.
rterial embolic events. During a median 22-month
ollow-up (IQR from 16 to 30 months), 14 patients had
rterial embolic events. In particular, seven patients suffered
n ischemic stroke, four patients a TIA, and three patients
ad other embolic complications. Thus, we observed a 1.2%
nnual rate of arterial embolism in a total follow up of 1,166
atient-years. The annual rates of ischemic stroke and TIA
ere 0.6% and 0.34%, respectively. A survival curve from
mbolic events is shown in Figure 1. One patient suffered a
emorrhagic stroke: he was not considered in the following
nalyses.
redictors of arterial embolic events. The comparison of
ifferent clinical and diagnostic characteristics among pa-
ients with and without embolism is shown in the third and
able 1. Clinical and Diagnostics Characteristics of All 725 Patie
vents
Variable
725 PatientsBaseline Patient Characteristics
ale gender, n (%) 360 (49.7%)
ge (yrs) 71  11
VEF (%) 56  10
AD (mm) 43.6  6.7
YHA functional class I, n (%) 306 (42.2%)
YHA functional class II, n (%) 317 (43.7%)
YHA functional class III, n (%) 50 (6.9%)
ardiovascular disease, n (%) 447 (61.7%)
alvular disease, n (%) 53 (7.3%)
F, n (%) 632 (87.2%)
trial flutter, n (%) 142 (19.6%)
trial tachycardia, n (%) 83 (11.4%)
aroxysmal AF, n (%) 504 (69.5%)
ersistent AF, n (%) 103 (14.2%)
reimplant atrial cardioversions, n (%) 299 (41.2%)
reimplant AF-related hospitalizations, n (%) 366 (50.5%)
umber of AF-related symptoms per patient 1.6  1.0
umber of symptomatic AF episodes per month 2 (1–8)
nticoagulant therapy, n (%) 264 (36.4%)
ntiplatelet therapy, n (%) 225 (31.0%)
ntiarrhythmic therapy, n (%) 378 (52.1%)
schemic cardiopathy, n (%) 105 (14.5%)
ypertension, n (%) 348 (48.0%)
ge 75 yrs, n (%) 235 (32.4%)
eart failure, n (%) 56 (7.7%)
iabetes, n (%) 59 (8.1%)
F 35%, n (%) 10 (1.4%)
AD 50 mm, n (%) 31 (4.3%)
rior embolic events, n (%) 13 (1.8%)
troke risk factors, n (%) 549 (75.7%)
umber of risk factors 1.2  0.9
ata are presented as the mean value  SD or median value (25th to 75th percen
chi-square test; ‡Mann-Whitney test; §t test.
AF  atrial fibrillation; EF  ejection fraction; LAD  left anterior descending
ssociation.ourth columns of Table 1. The percentage of patients with erior embolism, ischemic heart disease, hypertension, dia-
etes, stroke risk factors was higher in patients with embolic
vents as compared to patients without them. The number
f stroke risk factors was also significantly higher in patients
ho exhibited embolic events.
Results of univariate and multivariate analysis are shown
n Table 2. Among patient baseline characteristics, univar-
ate analysis associated ischemic heart disease, prior embolic
vents, diabetes, hypertension, and anticoagulant use as
hose associated with a significantly higher risk of embolic
vents. Furthermore, for each additional stroke risk factor,
e observed an increase by a factor of 2.7 in the risk of
mbolic events. Multivariate logistic analysis showed that
mbolic events are independently associated with ischemic
eart disease (7.0 OR, 95% CI 2.3 to 21.3, p 0.001), prior
mbolic event (7.3 OR, 95% CI 1.2 to 43.9, p  0.029),
iabetes (5.0 OR, 95% CI 1.2 to 15.7, p  0.032), and
ypertension (4.1 OR, 95% CI 1.1 to 15.6, p 0.036). Cox
ultivariate analysis, adjusted for previously shown embo-
ism predictors, demonstrated that the occurrence of AF
711 Patients Without, and 14 Patients With Cerebral Ischemia
711 Patients With No
Embolic Events
14 Patients With
Embolic Events p Value
351 (49.4%) 9 (64.3%) 0.268†
71  11 73  6 0.515§
56  10 54  12 0.582§
43.5  6.8 46.1  3.0 0.280§
302 (45.8%) 4 (28.6%) 0.414*
310 (47.0%) 7 (50.0%) 0.632*
47 (7.1%) 3 (21.4%) 0.065*
436 (61.3%) 11 (78.6%) 0.189†
51 (7.2%) 2 (14.3%) 0.273*
619 (87.1%) 13 (92.9%) 1.000*
138 (19.4%) 4 (28.6%) 0.492*
80 (11.3%) 3 (21.4%) 0.434*
494 (69.8%) 10 (71.4%) 1.000*
100 (14.1%) 3 (21.4%) 0.434*
292 (41.1%) 7 (50.0%) 0.501†
356 (50.1%) 71.4% (10) 0.113†
1.6  1.0 1.7  1.1 0.754§
2 (1–8) 4 (1–19) 0.544‡
255 (35.9%) 9 (64.3%) 0.029†
220 (30.9%) 5 (35.7%) 0.772*
371 (52.2%) 7 (50.0%) 0.872†
98 (13.8%) 7 (50.0%) 0.002*
337 (47.4%) 11 (78.6%) 0.021†
230 (34.0%) 5 (38.5%) 0.771*
53 (7.5%) 3 (21.4%) 0.086*
55 (7.7%) 4 (28.6%) 0.021*
10 (1.4%) 0 (0.0%) 1.000*
31 (10.3%) 0 (0.0%) 1.000*
11 (1.5%) 2 (14.3%) 0.024*
535 (75.2%) 14 (100.0%) 0.028*
1.2  0.9 2.3  1.2 0.004§
or continuous variables and number and percentage of patients. *Fisher exact test;
nary artery; LVEF  left ventricular ejection fraction; NYHA  New York Heartnts,
tile) fpisodes longer than one day was independently associated
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Arterial Embolism in Bradycardia Patients November 15, 2005:1913–20ith arterial embolism (3.1 hazard ratio, 95% CI 1.1 to
0.5, p  0.044). Occurrence of AF episodes longer than 5
in was not associated with a significantly higher risk of
mbolic events.
The percentages of patients with at least one device-
etected AF recurrence during the whole observational
eriod longer than, respectively, 5 min and 1 day are shown
n Table 3, subdividing the patients according to the
resence or absence of arterial embolism in the follow-up.
he percentage of patients with device-detected AF recur-
ences longer than one day was higher (71.4% vs. 41.2%, p
0.03 with Fisher exact test) in patients with arterial
mbolism as compared to patients without it. No significant
ifferences were found when limiting the analysis to shorter
bservational periods (i.e., to the first 3 months, the first 6
onths, or the first 12 months of follow-up).
Figure 1. Kaplan-Meier cumu
able 2. Results of Univariate and Multivariate Analysis
Patient Characteristics*
Univariate Analysis
p Value OR Lower
YHA functional class III 0.058 3.55 0.96
ardiovascular disease 0.201 2.31 0.64
rior hospitalizations 0.126 2.49 0.78
nticoagulant use 0.038 3.22 1.07
schemic cardiopathy 0.001 6.26 2.15
ypertension 0.032 4.07 1.13
eart failure 0.067 3.39 0.92
iabetes 0.010 4.77 1.45
rior embolic event 0.004 10.6 2.12
umber of risk factors†§ 0.0001 2.67 1.67
All patient characteristics that were associated to p values lower than 0.2 in the ho
onsidered for univariate analysis. †When considering the number of stroke risk fact
ncreasing by one the number of risk factors (i.e., one risk factor more means increasing
he risk of embolism associated with the presence of the considered patient character
.05 at univariate analysis were considered for multivariate analysis. §The number o
orrelated with ischemic cardiopathy, hypertension, and prior embolic events.
NYHA  New York Heart Association; OR  odds ratio.Kaplan-Meier survival from embolic events comparing
he two groups of patients with and without AF episodes
onger than one day during the follow-up is shown in Figure
. Log-rank statistics showed an incidence of arterial em-
olism significantly (p  0.03) higher in patients with such
F recurrences than in patients without them. We did not
bserve any significant difference by comparing with the
ame method the two groups of patients with and without
F episodes longer than 5 min.
ntithrombotic therapy and risk factors. After implanta-
ion, 489 (67.4%) patients were discharged with a pharma-
ological therapy to prevent thromboembolism. In particu-
ar, 264 patients were treated with oral anticoagulant (70%
arfarin and 30% acenocumarol) to maintain the interna-
ional normalized ratio in the range between 2 and 4, while
25 patients were treated with antiplatelet agents (76%
survival from embolic events.
Multivariate Analysis‡
Upper p Value OR Lower Upper
13.2
8.36
8.02
9.71 0.061 2.95 0.95 9.31
18.2 0.001 6.99 2.30 21.3
14.7 0.036 4.14 1.10 15.6
12.5
15.7 0.032 4.99 1.20 15.7
53.1 0.029 7.32 1.22 43.9
4.26
eity comparison between patients with and without embolic events (Table 1) were
e OR represents the increase in the risk of having an embolic event associated with
bolism risk by a factor of 2.7). For all other patient characteristics, the OR represents
r disease. ‡All patients’ characteristics that were associated with p values lower than
e risk factors was not considered in multivariate analysis because it was significantlymogen
ors, th
the em
istic o
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November 15, 2005:1913–20 Arterial Embolism in Bradycardia Patientsspirin, 14% indobufene, and 10% ticlopidine); 236 patients
32.6%) did not receive any anticoagulant or antiplatelet
reatment.
The distribution of enrolled patients, of patients treated
ith antiplatelet agents, of patients treated with anticoag-
lation therapy, of patients who suffered embolic events,
nd the distribution of embolism annual rate is shown in
able 4 as a function of the number of embolism risk factors
xhibited at baseline. During follow-up, anticoagulation
herapy was started in two patients at the time of embolic
vents.
iagnostic data. Several characteristics measured by de-
ice diagnostics were compared among two groups of
atients: 14 patients with arterial embolic events and 711
atients without arterial embolic events. In order to build a
ontrol group more homogeneous than the general popula-
ion to the group of subjects with the event, we also
ubselected a third group of 535 patients who had stroke
isk factors but who did not suffer arterial embolic events
uring follow-up. These groups did not differ in terms of
trial pacing percentage (69  34 vs. 74  26 vs. 74  26),
entricular pacing percentage (72 32 vs. 70 32 vs. 70
1), AF burden (280  498 vs. 151  298 vs. 150  294
in per day), number of AF episodes (2,185  4,719 vs.
,560  4,240 vs. 1,615  4,523), or device-defined
ercentage of ATP success (40  29 vs. 47  30 vs. 46
30).
able 3. Percentage of Patients With AF Episodes of Given Dur
vents
71
With No
ercentage of patients with AF episodes 5 min
ercentage of patients with AF episodes 1 day
Fisher exact test.
AF  atrial fibrillation.igure 2. Kaplan-Meier cumulative survival from embolic events for patients w
ithout AF recurrences or with AF episodes shorter than one day.ISCUSSION
ain study findings. This study is the first to report on
mbolic events during a long-term follow-up (1,166
atient-years) on a large cohort of patients paced for
radycardia, suffering from AF, and implanted with a
acemaker capable of atrial therapies delivery. About 36% of
he patients were anticoagulated with warfarin and aceno-
umarol according to the usual clinical practice (23).
Our data confirm that prior embolism, ischemic cardiop-
thy, hypertension, diabetes mellitus, and the presence of
ny stroke risk factor are independently associated with
mbolic events.
Furthermore, our results show that, in a population of
acemaker patients suffering from AF, device-detected AF
ecurrences longer than one day are independently associ-
ted with embolic events. Atrial fibrillation duration longer
han one day could certainly be a simple parameter to be
sed in clinical practice to guide anticoagulation therapy.
rterial embolism annual rates. Embolic risk has been
xtensively studied in the general population of patients
ith AF treated with conventional pharmacological agents
6,7,24,25). On the other hand, only limited and recent data
re available (3,15) about patients with bradycardia and
oexisting AF. Our data show a yearly incidence of arterial
mbolism in general and of ischemic stroke in particular of
.2% and 0.6%, respectively.
for the Group of Patients With and Without Arterial Embolic
ients
olic Events
14 Patients
With Embolic Events p Value
% 78.6% 1.00*
% 71.4% 0.03*ation
1 Pat
Emb
73.8
41.2ith atrial fibrillation (AF) episodes longer than one day and for patients
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Arterial Embolism in Bradycardia Patients November 15, 2005:1913–20Investigators of the Canadian Trial Of Physiologic Pac-
ng (CTOPP) (3) enrolled 2,568 patients and observed an
nnual stroke rate of 1.1% in the patient group with
entricular pacing and of 1.0% in the group with physio-
ogical pacing. Investigators of the MOST study (15)
bserved an annual rate of ischemic stroke equal to 1.4%,
ith no clear differences according to pacing mode.
Anticoagulant therapy may explain the observation of a
ower annual rate for stroke observed in our study compared
ith the MOST study (15). As a matter of fact, 32% of
atients in our study and 24% in the MOST study had
nticoagulant therapy. The percentage of anticoagulated
atients (34%) in the CTOPP study (3) was similar to ours.
n alternative hypothesis could be that atrial pacing, with
reventive algorithms and/or antitachycardia therapies, may
ave some protective action against thromboembolism, by
reventing or suppressing AF triggers and terminating
egular and slow atrial tachyarrhythmias. There are no
ublished data to support this hypothesis, which should be
ested in a prospective randomized trial. Unfortunately, such
study would require in practice a very large sample size,
ue to the very low expected event rate (3,15) and to the
ossible occurrence in an elderly population of stroke with
tiologies other than left atrium cardiogenic embolism
which may be hypothetically affected by atrial pacing), such
s left ventricle embolism, carotid and aortic atherosclerosis,
r hypoperfusion of small arteriolar beds.
redictors of embolic events. Previous studies (25,26)
bout AF patients without bradycardia identified ischemic
ardiopathy, hypertension, diabetes mellitus, increasing age,
revious TIA or stroke, heart failure, low ventricular func-
ion, and large left atrium dimensions as independent
redictors of stroke. Our data confirm that ischemic cardi-
pathy, hypertension, diabetes mellitus, and prior embolism
re independently associated with embolic events for our
opulation.
mbolic events and AF. The percentage of patients with
evice-detected AF recurrences longer than one day was
ignificantly higher among patients who suffered arterial
mbolism than among patients without embolism. Multi-
ariate analysis, adjusted for embolism prognostic factors,
emonstrated that patients with AF recurrences longer than
ne day were 3.1  more likely to suffer arterial embolism.
inally, Kaplan-Meier survival analyses showed that em-
olic events were significantly more frequent in patients
ith AF episodes longer than one day when compared with
able 4. Distribution of Patients, Antiplatelet Therapy, Anticoag
unction of Embolism Risk Factors
Number of Risk Factors 0
atients, n (%) 176 (24.3%)
atients, on antiplatelet agents, n (%) 38 (21.6%)
atients on anticoagulant therapy, n (%) 62 (35.2%)
atients with arterial embolism, n (%) 0 (0.0%)
rterial embolism annual rate (%) 0.0%atients without AF or with shorter AF recurrences. olotzer et al. (16) recently showed that device-detected AF
pisodes longer than 5 min are associated with a two-fold
ncrease in risk of death or stroke. In our results occurrence
f AF episodes longer than 5 min was not associated with
igher embolic risk: this is probably due to the fact that in
ur patient population (i.e., bradycardia patients with his-
ory of frequent symptomatic AF episodes) short AF recur-
ences were very common, occurring in about 80% of our
atients. Considering the results of the present study, and
he findings by Glotzer et al. (16), antithrombotic therapy
hould be considered in patients with device-detected AF
ecurrences.
linical implications of our study. Greenspon et al. (15)
howed a higher risk of embolism in patients found in AF
uring follow-up visits. There could be important limita-
ions associated to limiting the selection of clinically evident
F (i.e., symptomatic or discovered by chance during a
outine follow-up) as a supplementary risk factor to guide
nticoagulant therapy, because patients may be exposed to
he risk of embolism by persistent asymptomatic and unde-
ected AF episodes. Our results show that, in patients paced
or bradycardia and suffering from frequent AF recurrences,
imple device daily diagnostics showing the time spent in
F could be useful to guide anticoagulant therapy. In
articular, it could suggest that the clinician start anticoag-
lation in patients with no other risk factors but with long
eriods of arrhythmia, or to request accurate international
ormalized ratio control, or to add antiplatelet drugs to
nticoagulant agents in specific patients. Device diagnostic
apabilities may be of particular importance in pacemaker
atients because pacing often results in rate smoothing,
sually decreasing patients’ symptomaticity.
mbolism and risk factors. Our data show that embolism
ccurred only in patients with stroke risk factors, that
mbolism risk is directly correlated to the number of risk
actors, and finally that the yearly incidence of embolism is
1% in patients with 1 risk factor and increases as a
unction of the number of cardiac or noncardiac risk factors.
mbolism and antithrombotic therapy. Warfarin has
een shown as highly effective, in particular more effective
han antiplatelet agents, in preventing stroke in patients
ith AF in several randomized trials (24,26–28), most
ikely by minimizing the formation of atrial thrombi.
Guidelines about antithrombotic therapy recommend
reventive oral anticoagulation in patients with valvular
eart disease, in patients 65 years old, or in the presence
n Therapy, Arterial Embolic Events, and Annual Rate as a
1 2 3 >4
43.9%) 167 (23.0%) 53 (7.3%) 11 (1.5%)
31.4%) 61 (36.5%) 21 (39.6%) 5 (45.5%)
33.3%) 71 (42.5%) 19 (35.8%) 6 (54.5%)
1.3%) 5 (3.0%) 3 (5.7%) 2 (18.2%)
74% 1.78% 3.13% 11.66%ulatio
318 (
100 (
106 (
4 (f additional risk factors for thromboembolic events (23).
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ere on anticoagulant therapy, even if we cannot state if
nternational normalized ratio values were in the expected
ange at the time of embolic events.
The choice of antithrombotic treatment in this study was
eft to the decision of the attending cardiologists who are
sed to managing anticoagulation therapy. The percentage
f patients on antiplatelet therapy, but not the percentage of
atients on anticoagulant agents, increased as a function of
atient stroke risk factors.
Among patients indicated for anticoagulation, those who
ctually were on anticoagulant agents were only 32.2% at
aseline and 41.2% at the end of the follow-up. This
ercentage is lower than those described in previous studies
29–34) outlining an important underutilization of antico-
gulation therapy. However, in the arterial embolic group,
he percentage of anticoagulated patients was up to 64%,
hich is average for this patient population (Table 1).
tudy limitations. The incidence of some embolic events,
uch as asymptomatic ischemic attacks, could have been
nderestimated because no systematic neurological imaging
rocedures were requested by the study. Underestimation of
he embolism risk, associated to AF episodes or other
nown stroke risk factors, cannot be excluded because the
atients with the greatest numbers of risk factors were also
elected for anticoagulation by their clinicians.
Low frequency of embolic events leaves considerable
oom for statistical error associated with the estimation of
rterial embolism annual rate or risk associated with predic-
ors of embolic events. Our study did not record systemat-
cally the level of anticoagulation, which was left to the
ttending cardiologist; therefore, we cannot discuss the
dequate anticoagulation level at the time of stroke. This
tudy did not collect information about contraindications to
he anticoagulation therapy; therefore, we were only able to
bserve the low use of anticoagulation agents in the referred
atients.
Our data should be limited to this studied population.
onclusions. Our study is the first to report thromboem-
olic complications on a long-term follow-up of a large
ohort of patients paced for bradycardia and suffering from
F, and therefore implanted with a pacemaker capable of
trial therapies delivery. Our data show a 0.6% annual stroke
ncidence and a 1.2% annual incidence of embolism in
eneral. Prior embolism, ischemic cardiopathy, hyperten-
ion, diabetes mellitus, and, in general, the presence of
troke risk factors resulted in the association of higher risk
f embolism in the observation period.
Patients with device-detected AF recurrences longer than
ne day had a risk of embolism 3.1 times increased as
ompared to patients without or with shorter AF recur-
ences, showing that AF recurrences longer than one day are
ndependently associated with arterial embolism. Anticoag-
lation therapy was underused in our patient population;
oreover, arterial embolic events were observed also innticoagulated patients. This datum suggests either atricter international normalized ratio monitoring or an
ddition of antiplatelet therapy.
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or a list of the investigators and centers participating in the
talian AT500 Registry, please see the online version of this
rticle.
